mRNA cancer vaccine – immunotherapy for colorectal cancer
BioNTech has announced a new mRNA therapeutic vaccine that has shown early success in treating colorectal cancer.
BioNTech has announced a new mRNA therapeutic vaccine that has shown early success in treating colorectal cancer.
Early results from clinical trials show that the new mRNA vaccine to treat pancreatic cancer, cevumeran, showed significant promise.
Project Veritas claims that Pfizer COVID-19 research employed some unethical studies to sell more vaccines. It is completely false.
Recent scientific research shows that the bivalent COVID-19 vaccines do not cause strokes despite early safety signals.
Pfizer and BioNTech have announced the start of a phase 1 clinical trial for a new mRNA vaccine that prevents both the flu and COVID-19. The new vaccine targets these two severe respiratory diseases with one jab.
Although during the past three years we have focused on the COVID-19 pandemic, the seasonal flu is also a dangerous disease. During the 2019-2020 flu season, the last one before COVID-19 mitigation efforts reduced the risk of flu, 390,000 Americans were hospitalized from the flu. And over 25,000 died.
So, a new mRNA vaccine (with all of its advantages to tailor the vaccine to the key antigens on the virus) that combines both flu and COVID-19 can be an effective weapon against these two diseases. In a couple of years, if all goes well, we will be able to get a season flu-COVID-19 mRNA vaccine that has been manufactured for the season’s prevalent variants of both diseases.
Let’s take a look at what we know about this new vaccine and the phase 1 clinical trial.
Read More »Combination flu and COVID mRNA vaccine starting clinical trials